Intranasal Administration of Self-Oriented Nanocarriers Based on Therapeutic Exosomes for Synergistic Treatment of Parkinson’s Disease
Abstract
The treatment of Parkinson's disease (PD) has been hindered by the complex pathologies and multiple membrane barriers during drug delivery. Although exosomes derived from mesenchymal stem cells (MSCs) have great potential for PD, MSC-derived exosomes alone could not fully meet the therapeutic requirements due to their limitation in therapy and delivery. Here, we develop a self-oriented nanocarrier called PR-EXO/PP@Cur that combines therapeutic MSC-derived exosomes with curcumin. PR-EXO/PP@Cur can be self-oriented across the multiple membrane barriers and directly release drugs into the cytoplasm of target cells after intranasal administration. With enhanced accumulation of drugs in the action site, PR-EXO/PP@Cur achieves three-pronged synergistic treatment to deal with the complex pathologies of PD by reducing α-synuclein aggregates, promoting neuron function recovery, and alleviating the neuroinflammation. After treatment with PR-EXO/PP@Cur, the movement and coordination ability of PD model mice are significantly improved. These results show that PR-EXO/PP@Cur has great prospects in treatment of PD or other neurodegenerative diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a PD mouse model, PR-EXO/PP@Cur decreased the concentration of α-syn aggregates, increased the amount of dopaminergic neurons in the substantia nigra, and improved motor function.
“In a PD mouse model, the PR-EXO/PP@Cur decreased the concentration of α-syn aggregates and increased the amount of dopaminergic neurons in the substantia nigra, and improved the motor function of the PD mice [262].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [262]
Cites
Inflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Li, J., Peng, H., Zhang, W., Li, M., Wang, N., Peng, C., Zhang, X., & Li, Y. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c08756 · Cited by 43 · see citing works
Self-citationExtracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26 · see citing works
- Authors
- Peng, H., Li, Y., Ji, W., Zhao, R., Lu, Z., Shen, J., Wu, Y., Wang, J., Hao, Q., Wang, J., Wang, W., Yang, J., & Zhang, X.
- Affiliations
- Chinese Academy of Sciences (CN)
- University of Science and Technology Beijing (CN)
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
- Corresponding author
- Zhang, Xin
- ORCID
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-01-05
- Volume
- 16
- Issue
- 1
- Pages
- 869-884
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W4206764354
- Cited by
- 205
- References
- 1
- Citations by year
- 2026: 30 · 2025: 59 · 2024: 58 · 2023: 45 · 2022: 13
- FWCI
- 14.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- ACS Nano (publishedVersion)
- PubMed (publishedVersion)
- Institute of Process Engineering, CAS Institutional Repository (submittedVersion)
- Funders
- Natural Science Foundation of Beijing Municipality (2192057)
- National Natural Science Foundation of China (21875254, 21905283, 22075289, 31771095, 32071391, 52073287)
- Beijing Nova Program (Z201100006820140)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- Parkinson's disease, mesenchymal stem cell-derived exosomes, intranasal drug delivery, curcumin, alpha-synuclein aggregation, neuroinflammation, neuroprotection, synergistic therapy, neurodegenerative diseases
- MeSH terms
- Administration, Intranasal, Animals, Curcumin, Parkinson Disease, Mice, Exosomes, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
